Research programme: anticancer therapeutics - Medpacto

Drug Profile

Research programme: anticancer therapeutics - Medpacto

Alternative Names: TEW 0201; UAI 201

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator YOUAI
  • Developer MedPacto
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Colorectal cancer; Malignant melanoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Colorectal-cancer in South Korea
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in South Korea
  • 01 Jul 2013 Medpacto acquires TEW 0201 from Youai
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top